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Abstract
Clinical resistance to chemotherapy is a frequent event in cancer treatment and is closely linked to poor outcome.
High-grade serous (HGS) ovarian cancer is characterized by p53 mutation and high levels of genomic instabil-
ity. Treatment includes platinum-based chemotherapy and initial response rates are high; however, resistance
is frequently acquired, at which point treatment options are largely palliative. Recent data indicate that platinum-
resistant clones exist within the sensitive primary tumor at presentation, implying resistant cell selection after treat-
ment with platinum chemotherapy. The AKT pathway is central to cell survival and has been implicated in platinum
resistance. Here, we show that platinum exposure induces an AKT-dependent, prosurvival, DNA damage response
in clinically platinum-resistant but not platinum-sensitive cells. AKT relocates to the nucleus of resistant cells where
it is phosphorylated specifically on S473 by DNA-dependent protein kinase (DNA-PK), and this activation inhibits
cisplatin-mediated apoptosis. Inhibition of DNA-PK or AKT, but not mTORC2, restores platinum sensitivity in a panel
of clinically resistant HGS ovarian cancer cell lines: we also demonstrate these effects in other tumor types. Re-
sensitization is associated with prevention of AKT-mediated BAD phosphorylation. Strikingly, in patient-matched
sensitive cells, we do not see enhanced apoptosis on combining cisplatin with AKT or DNA-PK inhibition. Insulin-
mediated activation of AKT is unaffected by DNA-PK inhibitor treatment, suggesting that this effect is restricted
to DNA damage–mediated activation of AKT and that, clinically, DNA-PK inhibition might prevent platinum-induced
AKT activation without interfering with normal glucose homeostasis, an unwanted toxicity of direct AKT inhibitors.
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Introduction
AKT (v-akt murine thymoma viral oncogene homologue/protein
kinase B [PKB]) is a serine/threonine kinase controlling physiologi-
cal processes such as cell growth, proliferation, survival and motil-
ity. Dysregulation of the AKT pathway is well described in cancer
(reviewed in Vivanco and Sawyers [1]) and has been implicated in
tumorigenesis and resistance to chemotherapy [2–6]. The canonical
pathway leading to AKT activation involves receptor tyrosine ki-
nase recruitment of phosphatidylinositol 3-kinase (PI3K) leading to
the conversion of phosphatidyl-inositol 4,5-diphosphate (PIP2) to
phosphatidyl-inositol 3,4,5-triphosphate (PIP3) at the cell mem-
brane. Subsequently AKT is recruited to the cell surface through in-
teraction with phosphatidyl-inositol 3, 4, 5-triphosphate. AKT is
activated after phosphorylation on two key residues: serine 473
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(S473) and threonine 308 (T308) [1]. Phosphorylation of T308 is
performed by 3-phosphoinositide–dependent kinase 1 (PDK1) [1].
The identity of the kinase responsible for phosphorylation of S473
has been more elusive; however, it has now been shown that mam-
malian target of rapamycin complex 2 (mTORC2) can catalyze this
reaction [7] as can DNA-dependent protein kinase (DNA-PK) [8,9],
integrin-linked kinase 1, mitogen-activated protein kinase–activated
protein kinase 2, protein kinase CβII (PKCβII), ataxia-telangiectasia
mutant, and ataxia-telangiectasia and Rad3 related, which are
thought to reflect the numerous cellular contexts in which AKT plays
a role [10].
Cisplatin and carboplatin are widely used agents in the treatment
in of cancers including ovarian, testicular, head and neck, and non–
small cell lung cancer where they act by forming covalent adducts
with the cellular DNA, leading to replicative and transcriptional
blockage and ultimately growth arrest and apoptosis. The clinical
use of platinum agents is, however, limited by the frequent develop-
ment of resistance, which is thought to occur through a variety of
mechanisms (reviewed in Agarwal and Kaye [11]). One of the key
mediators of platinum resistance is the AKT pathway. Hyperactiva-
tion of the PI3K/AKT can occur by mutations involving p110/p85
PI3K subunits, AKT isoforms, or the negative regulator of AKT,
PTEN (phosphatase and tensin homolog deleted on chromosome
10) (reviewed in Stronach et al. [12]). Numerous additional compo-
nents of the AKT pathway have been implicated in chemoresistance.
Recently, a positive feedback loop in which AKT activates FOXO3a,
which in turn enhances the expression of PI3K p110α, has been as-
sociated with doxorubicin resistance in leukemic cells [13]. AKT
negatively regulates apoptosis-initiating factor in cisplatin-resistant
ovarian cancer cells to prevent caspase-independent cisplatin-induced
apoptosis [14]. In malignant melanoma cells, knockdown of PRAS40
(a downstream target of AKT) or AKT3 enhanced the apoptotic re-
sponse to staurosporine [15]. In addition, AKT prevents mitochon-
drial accumulation of p53 and release of cytochrome c and Smac/
DIABLO, conferring cisplatin resistance to ovarian cancer cells [3].
The mechanism by which cisplatin activates the AKT survival re-
sponse in clinical platinum resistance is currently undetermined.
We used a series of matched clinically platinum-sensitive/resistant
paired cell lines [16–18] to assess the role of DNA-PK in the acti-
vation of AKT in response to cisplatin and show that DNA-PKcs is
expressed in high-grade serous (HGS) ovarian cancer cells and phos-
phorylates AKT at S473 in response to cisplatin-induced DNA
damage in cells with clinically acquired resistance to cisplatin but
not in matched sensitive cells. Furthermore, we show colocalization
and binding of DNA-PKcs and AKT in the nuclei of resistant but
not sensitive tumor cells and that inhibition of DNA-PK prevents
AKT activation and enhances sensitivity to cisplatin in platinum-
resistant ovarian cancer cells. We also show that activation of AKT
by DNA-PK occurs in response to cisplatin, but not insulin, across a
range of tumor types, suggesting a nuclear, DNA damage–mediated
pathway distinct from canonical cell surface PI3K/AKT activation.
These findings have implications for the clinical management of
ovarian and other cancers.
Materials and Methods
Cell Lines and Reagents
The paired HGS ovarian carcinoma cell lines PEO1, PEO4, PEO6,
PEA1, PEA2, PEO14, and PEO23 were obtained from Dr Simon
Langdon (Edinburgh, UK) and have been described [16–19]. Cell
lines were verified by STR DNA fingerprinting. In the matched pairs
PEO1 versus PEO4/PEO6, PEA1 versus PEA2, and PEO14 versus
PEO23, the first set of cell lines (PEO1, PEA1, and PEO14) was
derived before and the second set (PEO4/PEO6, PEA2, PEO23)
was derived after the onset of acquired clinical platinum resistance.
Paired cell lines PEO1/PEO4, PEA1/PEA2, and PEO14/PEO23 were
sequenced for COSMIC mutations as described previously [20].
Clear cell ovarian cancer cell line, HCH1, was a gift from Dr Kigawa
Tottori University, Japan. SKOV3, PANC-1, A549, HCC95, and PC3
cells were obtained from European Collection of Cell Cultures. Cisplatin
response in vitro was reported elsewhere [18], confirming maintained
clinical platinum resistance in vitro. IC50 (inhibitory concentration 50%)
values for ovarian lines are summarized in Table W1. Cells were main-
tained in RPMI 1640 media (10% fetal calf serum) at 37°C/5% CO2.
Antibodies and suppliers were as follows: AKT1, AKT2, AKT3, panAKT,
pAKT-S473, pAKT-T308, pBAD-S136, pPRAS40, integrin-linked
kinase 1, and Rictor (Cell Signaling Technology, Danvers, MA); DNA-
PKcs (Thermo Scientific, Waltham, MA); γH2AX (Abcam, Cambridge,
United Kingdom); Lamin A/C (Millipore, Billerica, MA); and β-tubulin
(Santa Cruz, Santa Cruz, CA).
Cell Proliferation and Apoptosis Assays
Cells were seeded in triplicate in 96-well trays and allowed to adhere
for 24 hours. Treatments were as described. Apoptotic assessment was
by detection of active caspase 3/7 using caspase Glo 3/7 assay (Promega,
Madison, WI) following the manufacturer’s protocol. Cell proliferation
was by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as described elsewhere [18]. Caspase activity was normal-
ized to cell density (MTT) data for each treatment. For isobologram
analyses, cells were seeded into 96-well plates and allowed to adhere.
The medium was replaced with serially diluted AKT inhibitor (API-2;
Berry & Associates, Dexter, MI) and left for 1 hour. Cisplatin was then
added in serial dilutions, from 50 to 0.391 μM in a matrix format
with inhibitor-treated cells. MTT assays were performed after three
doubling times. The IC50 values were calculated for each drug alone
and plotted onto an IC50-(cisplatin)-versus-IC50 (API-2) graph to gen-
erate the isobole. Combination values that achieved IC50 growth inhi-
bition ±10% were plotted, and superadditivity was indicated by points
below the isobole.
Western Blot and Immunoprecipitation
Western blots were preformed as described previously [18]. For
immunoprecipitation (IP), cells were treated with 25 μM cisplatin
or control for 24 hours as appropriate before lysis (IP lysis buffer:
1% Triton X, 150 mM NaCl, 50 mM Tris-HCl, 0.2 mM Na3VO4,
50 mM NaF, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 25 μg/ml aprotinin, 25 μg/ml leupeptin). One hundred micro-
liters of protein G sepharose (PGS) beads was washed in phosphate-
buffered saline (PBS) and then IP lysis buffer. To address nonspecific
protein binding to PGS, 1 mg of sample lysate was incubated with 30 μl
of PGS rotating at 4°C for 1 hour. Precleared lysates were incubated over-
night at 4°C with 2 μg of primary antibody. Thirty microliters of PGS
was added to each sample, including whole-cell extract control, and incu-
bated rotating at 4°C before centrifuging at 10,000 rpm for 2 minutes.
Collected beads were washed three times with IP lysis buffer and then
dissolved in 50 μl of 2× sample buffer (1% Triton X, 150 mM NaCl,
50 mMTris-HCl, 2 mMEDTA, 1mMPMSF) at 95°C for 10 minutes.
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Equal volumes of the IP sample, extract-only, and controls were sepa-
rated and visualized by Western blot as described previously.
Small Interfering RNA Transfection and Apoptosis Assay
Cells grown to 60% confluence in six-well plates were transfected
at 100 nM final small interfering RNA (siRNA) concentration
(Dharmacon, Lafayette, CO). Cells were retransfected after 48 hours.
SiRNAs in 1× siRNA buffer were mixed with 2 μl of transfection
reagent no. 1 (Dharmacon) per transfection in a total volume of
400 μl with Opti-MEM (Invitrogen, Paisley, United Kingdom). Af-
ter 30 minutes of incubation, siRNAs were added to 1600 μl of
antibiotic-free RPMI 1640/10% fetal calf serum on cells. Twenty-four
hours after the second transfection, cells were reseeded. Cells in six-well
trays were incubated for 48 hours, and protein samples were prepared.
Cells in clear and opaque 96-well trays were treated identically: for each
transfection condition, 24 hours after seeding, three replicate wells were
treated with 25 μM cisplatin and three wells were left untreated. After
24 hours, cells’ caspase activation was measured by caspase Glo 3/7, and
viable cell numbers were inferred by MTT assay.
Immunofluorescent Microscopy
Coverslips (VWR International, Lutterworth, United Kingdom)
were treated with 1 M HCl before cell seeding and incubation for
24 hours. After serum starvation and indicated treatments, cells were
washed with PBS and then fixed/permeabilized at 37°C for 30 minutes
with 4% paraformaldehyde/1.8% Triton X-100/PBS. Coverslips were
blocked in 10% goat serum/2%bovine serum albumin/PBS for 30min-
utes, washed with PBS, and incubated with primary antibodies over-
night at 4°C. Coverslips were washed in PBS and incubated with
fluorochrome-conjugated secondary antibodies (fluorescein isothiocya-
nate anti-goat IgG, fluorescein isothiocyanate anti-rabbit IgG, Alexa-
Fluor 555 anti-mouse IgG, and Alexa-Fluor 488 goat anti-rabbit IgG,
1:500; Invitrogen) and directly labeled actin stain (Alexa-Fluor 633
phalloidin; Invitrogen) in blocking buffer for 1 hour. Cells were rinsed
in PBS andmounted onto slides usingVECTASHIELDmedia contain-
ing 4′,6-diamidino-2-phenylindole (Vector Laboratories, Peterborough,
United Kingdom). Slides were visualized on an inverted confocal
microscopy system (TCS SP5; Leica, Wetzlar, Germany).
Subcellular Fractionation
Cells were serum-starved overnight and then treated with 25 μM
cisplatin for the indicated time points. Cells were washed with cold PBS,
and pellets were collected by trypsinization. Fractionation was by nuclear/
cytosolic or mitochondrial/cytosolic fractionation kits according to the
manufacturer’s protocols (BioVision, Mountain View, CA).
Results
AKT Is Activated in Response to Cisplatin Treatment in
Clinically Platinum-Resistant Cells Only and AKT
Inhibition Restores Platinum Sensitivity
Previously, we reported upregulation of PIK3R1, the p85α sub-
unit of PI3K, in clinically platinum-resistant ovarian cancer cells
[18] and showed that knockdown of PIK3R1 enhanced sensitivity
to cisplatin. We therefore examined activation of AKT in response
to cisplatin in clinically derived platinum-sensitive and -resistant ovar-
ian cancer cells. Sensitive cells (PEO1) showed minimal platinum-
induced phosphorylation of AKT-S473 during a 48-hour period.
Conversely, clinically platinum-resistant cells cultured from the same
patient (PEO4) after relapse, S473 phosphorylation induction is
evident from 4 hours after cisplatin (Figure 1A). Densitometry in-
dicates three- to four-fold induction of S473 8 hours after cisplatin
treatment maintained at 48 hours (Figures 1A and W1A). Interest-
ingly, previous analysis of these matched cell line pairs indicated that
platinum-resistant cells existed clinically at presentation and were se-
lected for by platinum therapy [16]. Our data suggest activation of
AKT after cisplatin treatment is a specific molecular feature of the re-
sistant tumor, emerging after clearance of sensitive cells by chemother-
apy, implicating AKT-mediated prosurvival signaling as a resistance
mechanism. Hence, we examined the effect of AKT inhibition on
platinum sensitivity using the small-molecule AKT inhibitor API-2
[21], which binds the PH domain of AKT preventing its activation
[22]. Figure 1B demonstrates a dose-dependent, API-2–mediated re-
duction in pAKT-S473 in the presence and absence of cisplatin (see
Figure W1B for densitometry). We hypothesized that prevention of
cisplatin-induced activation of AKT may restore apoptotic potential,
and we therefore compared caspase 3/7 activation in response to cis-
platin in the presence and absence of API-2. Figure 1, C and D, dem-
onstrates enhancement of apoptotic induction in platinum-resistant
ovarian cancer cells (PEO4, PEA2, PEO23, and SKOV3) after in-
hibition of AKT, suggesting that AKT inhibition primes the resistant
cells for apoptosis, after which a cytotoxic insult from cisplatin pro-
vokes caspase 3/7 activation. This has implications for AKT inhibitor
strategies, suggesting that AKT inhibitor monotherapy may be inactive
in this setting compared with combination with platinum. Strikingly,
AKT inhibition seems to have little effect on platinum-induced caspase
activity in the platinum-sensitive lines PEO1, PEA1, and PEO14 de-
rived from the same patients as the resistant lines (Figure 1, C and
D). This is in keeping with data from Figure 1A, indicating that AKT
is not activated after cisplatin treatment in sensitive cells, suggesting
that this is a truly acquired molecular mechanism underlying plati-
num resistance in HGS ovarian cancer. In addition, AKT inhibition
was also effective in clear cell ovarian cancer cells (HCH-1), pancreatic
(PANC-1), and prostate (PC3) cancer cells (Figure W2). To further
assess the combinatorial effect of cisplatin and API-2, we performed
isobologram analyses [23], which indicated synergistic interaction
between cisplatin and API-2 in resistant PEO4 cells (Figure 1E).
Cisplatin Resistance Is Not Determined by a Single,
Common AKT Isoform
A drawback to targeting AKT therapeutically is its fundamental role
in biological processes such as insulin signaling and normal growth
control [24]. Studies of AKT1, 2, and 3 knockout mouse models
indicate nonredundancy in AKT isoform function [25]. We there-
fore considered the potential of single-isoform effects in platinum
resistance. SiRNAs to each of the three isoforms of AKT, namely,
AKT1(PKBα), AKT2(PKBβ), and AKT3(PKBγ), in platinum-resistant
cell lines showed that each cell line tested seems to have an isoform
dependency: PEO23 and SKOV3 require AKT1 for cisplatin resis-
tance, PEA2 requires AKT2, whereas PEO4 requires AKT3 (Figure 2,
A–D). To determine whether known activating mutations in PI3K
and AKT were responsible for the drug-resistant phenotype, we se-
quenced DNA from each of the paired cell lines. No mutations were
found at tested sites in any AKT isoform or in PIK3CA or PIK3R1.
Furthermore, 118 additional common variants were screened in 29
cancer associated genes, which identified a heterozygous G2677A
variant in ABCB1 in PEA2 and a heterozygous G1154A variant in
VEGFA in PEA1 as the only alterations that differed between sensitive
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Figure 1. AKT inhibition reverses resistance to platinum treatment in ovarian cancer cells. Western blot indicates differential AKT-S473
response to platinum treatment between platinum-sensitive and -resistant cells from the same patient (A) and shows inhibition of pAKT
by AKT inhibitor API-2 (B). Visual appearance of platinum-sensitive (PEA1) and matched resistant (PEA2) cells illustrates enhancement of
cytotoxicity in resistant cells 8 hours after combination treatment with 20 μMAPI-2 and equitoxic cisplatin (5 μM PEA1; 25 μM PEA2) (C).
Caspase 3/7 assays 24 hours after treatment with cisplatin and/or API-2 reveal enhanced apoptosis when combining API-2 with cisplatin
compared to platinum alone in platinum-resistant cell lines: PEO4 (P = .019), PEA2 (P = .003), PEO23 (P = .042), and SKOV3 (P = .02)
(paired t tests). Conversely, platinum-induced apoptosis is more modestly enhanced in the matched platinum-sensitive cells lines PEO1,
PEA1, and PEO14, with only PEA1 achieving statistical significance (P = .01) (D). Isobologram analysis of acquired platinum-resistant
PEO4 cells supports the synergistic interaction between platinum and API-2 (E). n ≥ 3. *P < .05. **P < .01.
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and resistant pairs. These changes are not thought to relate to platinum
resistance (for further details and discussion, see Table W2). It seems
that no single AKT isoform is specifically selected in platinum resis-
tance; hence, pan-AKT inhibition is more rational in this setting.
mTORC2 Does Not Phosphorylate AKT-S473 in Response to
Cisplatin in Platinum-Resistant Cells
We hypothesized that the identification of the kinase responsible
for activation of AKT in response to cisplatin treatment might sug-
gest a therapeutic target with better phenotypic specificity than tar-
geting AKT itself.
The best-characterized kinase phosphorylating AKT-S473 is
mTORC2, a protein complex composed of mTOR, mLST8, and
Rictor [7]. We performed siRNA to the Rictor subunit of mTORC2
and show that knockdown had no significant effect on platinum re-
sponse (Figure 3A). Furthermore, Rictor knockdown has no effect
on platinum-mediated phosphorylation of AKT-S473 in resistant
SKOV3 cells (Figure 3A). Rapamycin treatment also fails to prevent
Figure 2. The functional effect of AKT in platinum resistance is not determined by a single common AKT isoform. After knockdown of
individual AKT isoforms 1, 2, and 3, cells were treated with cisplatin, and caspase 3/7 activation was assayed for platinum-resistant cell
lines PEO4 (A), PEA2 (B), PEO23 (C), and SKOV3 (D). Isoform-specific knockdowns are indicated by Western blot (right panels). Statis-
tically significant differences, compared with control transfections, are indicated: *P < .05. **P < .01.
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cisplatin-mediated induction of pAKT-S473 and actually seems to
inhibit the apoptotic response to cisplatin (Figure 3B). Finally, IP in
the presence and absence of platinum failed to reveal any interaction
between Rictor and AKT (pS473; Figure 3C ). We conclude that
mTORC2 is not involved in cisplatin-mediated activation of AKT
and that mTOR in general is probably not involved in the downstream
prosurvival effects of activated AKT in platinum-resistant cells.
DNA-PK Phosphorylates AKT-S473 in Response to Cisplatin
in the Nucleus of Platinum-Resistant, But Not Sensitive,
Cells and Enhances Cisplatin Response in Clinically Resistant
Cells without Affecting Insulin-Mediated AKT Activation
We next considered if DNA-PK was responsible for platinum-
mediated prosurvival activation of AKT seen on acquisition of clin-
ical platinum resistance in ovarian cancer. Interaction between AKT
and DNA-PK was detected by IP in platinum-resistant cells (Fig-
ures 4A and W3A). By contrast, this interaction was either not seen
or was less readily detectable in intrapatient-matched sensitive cells
(Figure 4A).
Knockdown of DNA-PKcs significantly enhanced apoptotic re-
sponse to cisplatin in PEO4-, SKOV3-, PEA2-, and PEO23-resistant
ovarian cancer cells (P < .05; Student’s t test) (Figures 4, B and C ,
and W3, B or C ). Western blot analysis showed that, in the absence
of DNA-PKcs, platinum-induced activation of AKT by phosphory-
lation at S473 was ablated. Phosphorylation of AKT at T308, known
to be catalyzed by PDK1, was unaffected by DNA-PKcs knockdown
confirming site specific activity and indicating that T308 phosphor-
ylation alone is insufficient for the platinum-resistant phenotype
(Figure 4, B and C ).
Given platinum’s mode of action, damaging DNA, and the role of
DNA-PK in DNA repair, we performed immunofluorescent con-
focal microscopy, which revealed nuclear accumulation of pAKT in
resistant cells within 30 minutes of platinum treatment with appar-
ent cytoplasmic redistribution by 8 hours (Figures 5A and W4). By
contrast, platinum-sensitive cells do not accumulate nuclear pAKT.
Nuclear pAKT was confirmed by subcellular fractionation experi-
ments (Figure 5B), which also indicated mitochondrial redistribu-
tion of pAKT at 8 hours (Figure 5C ). Together with the IP and
siRNA data (Figure 4), this suggests AKT is activated in the nucleus
by DNA-PKcs after cisplatin-induced DNA damage in platinum-
resistant, but not platinum-sensitive, cells and subsequently redis-
tributes to mitochondria.
Figure 3. AKT is not activated by mTOR-Rictor in response to platinum, and its inhibition does not enhance platinum-mediated apopto-
sis. Caspase 3/7 activation was measured 24 hours after cisplatin treatment in control and Rictor siRNA-transfected cells, which indi-
cated no enhancement of apoptosis or effect on pAKT-S473 (A). Treatment of sensitive (PEO1) and resistant (PEO4) cells with the mTOR
inhibitor rapamycin (200 nM) and/or cisplatin (25 μM) indicated no enhancement of platinum sensitivity on combination with rapamycin
and no effect on AKT phosphorylation (B). No interaction between Rictor and pAKT was detected by IP in the presence or absence of
25 μM cisplatin (2-hour exposure) in platinum-resistant PEO4 cells (C).
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Next we considered the broader effects of these initial observations
using the DNA-PK inhibitor, NU7026 [26]. Figure 6A demon-
strates a dose-dependent inhibition of DNA-PKcs phosphorylation at
serine 2056 by NU7026 in resistant PEO4 cells, consistent with
inhibition of catalytic activity and hence autophosphorylation of
DNA-PKcs at this site [27]. NU7026 significantly sensitized platinum-
resistant SKOV3 cells and the intrapatient-matched platinum-resistant
cells (PEO4, PEO23, and PEA2) to platinum-induced caspase 3/7
activity with little effect on their platinum-sensitive counterparts
(PEO1, PEO14, and PEA1; Figures 6B and W5). As with DNA-
PKcs siRNA, enhancement of apoptosis was associated with loss of
platinum-induced pAKT-S473 but not T308 (Figure 6C ). We ex-
amined the cellular levels of phosphorylated BAD (S136), an AKT-
mediated phosphorylation event that inhibits this proapoptotic
BCL-2 family member [28]. Figure 6D shows that the AKT inhibitor
API-2 decreases pBAD-S136 in the presence and absence of cis-
platin treatment, consistent with a direct effect on AKT. NU7026
also prevents pBAD accumulation in the presence of cisplatin; how-
ever, it has no effect on pBAD levels in the absence of platinum, con-
sistent with the role of DNA-PK as a DNA damage–specific activator
of AKT and consistent with the reversal of cisplatin resistance ob-
served in Figures 4 and 6.
Figure 4. DNA-PKcs phosphorylates AKT in response to cisplatin treatment and mediates platinum resistance. IP of DNA-PKcs in a panel
of platinum-sensitive and -resistant cells indicates interaction with AKT in resistant cells, in the presence and absence of 25 μM cisplatin
(2-hour exposure), which is not seen in sensitive PEO1 and PEA1 cells and is only detectable on platinum treatment in sensitive PEO14
cells (A). Knockdown of DNA-PKcs in platinum-resistant PEO4 (B) and SKOV3 (C) cells increases the apoptotic induction on platinum
treatment compared with control transfections (P = .01, PEO4: P = .0003, SKOV3). Western blots indicate specific loss of cisplatin-
induced phosphorylation of AKT-S473 but not T308. n = 3. *P < .05. ***P < .001.
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We also looked at the effect of DNA-PK inhibition on platinum
response in a broader panel of cell lines: HCH-1 ovarian clear cell,
A549 and HCC95 lung cells, and PANC-1 pancreatic cells (Fig-
ure W5). Each showed significant enhancement of platinum-mediated
caspase 3/7 induction on DNA-PK inhibition.
Clinical use of AKT inhibitors has been associatedwith hyperglycemia/
hyperinsulinemia reflecting the central role of AKT in insulin sig-
naling [24]. We sought to determine whether platinum-induced,
DNA-PK–mediated AKT activation occurred independently of
insulin-induced AKT activation in cancer, as has been indicated for
γ-irradiation–induced damage in HUVEC cells [8]. Figures 6C and
W5 show that DNA damage induced by either γIR or cisplatin activates
AKT through a DNA-PK–dependent phosphorylation at AKT-S473.
However, insulin stimulation induces pAKT-S473 in a DNA-PK–
independent manner in PEO4, PEO23, SKOV3, PANC-1, and
A549 cells. These data have implications for clinical inhibition of
AKT in combination with DNA-damaging chemotherapeutics, sug-
gesting that DNA-PK inhibition may circumvent the effects on glu-
cose homeostasis seen with direct AKT inhibitors while maintaining
the proapoptotic effect associated with preventing DNA damage–
induced AKT activation–mediated survival.
Discussion
HGS ovarian cancer is the most common subtype of the ovarian
neoplasms and is associated with poor outcome. High TP53 muta-
tion rate and defects in homologous recombination repair create
the genomic instability that underlies cellular heterogeneity in this
tumor type (reviewed in Bowtell [29]). Interestingly, DNA damage
response defects in HGS ovarian cancer render the cells typically
sensitive to the initial treatment with cytotoxic chemotherapy. How-
ever, this feature also generates the cellular heterogeneity that has
been postulated to account for the high frequency of acquired re-
sistance to platinum-based chemotherapy. Cooke et al. [16] reported,
using the same cell line models studied here, that resistant and
sensitive cells from a single patient contain mutually exclusive ge-
nomic features, indicating that acquired resistance does not develop
by mutation to the sensitive tumor on platinum exposure but by
selection of preexisting platinum-resistant subclones within the
heterogeneous tumor mass. These observations have significance in
understanding and managing clinical platinum resistance. By impli-
cation, if resistant cells are present in the presenting tumor, targeting
of resistant cells could be applied to the front-line setting to delay
resistant relapse.
Figure 5. After platinum treatment, AKT is translocated to the nucleus of cisplatin-resistant but not matched cisplatin-sensitive cells.
Immunofluorescent microscopy of platinum-sensitive (PEO1) and -resistant (PEO4) cells after treatment with 25 μM cisplatin reveals
induction and nuclear accumulation of pAKT-S473 in PEO4 but not PEO1. The enlarged box indicates nuclear colocalization of pAKT
and DNA-PKcs in PEO4 cells 30 minutes after platinum treatment. After an 8-hour exposure to cisplatin, pAKT appears redistributed
to the cytoplasmic compartment in PEO4. Counterstaining of nuclei is indicated in blue in the merged images (secondary antibody–
only controls are shown in Figure W4; A). Western blot of fractionated PEO4 cells confirms early nuclear location of pAKT after
25 μM cisplatin with delayed cytoplasmic accumulation. Purity of fractions is indicated by β-tubulin (cytoplasmic) and Lamin A/C
(nuclear) markers (B). Mitochondrial fractionation indicates that punctate staining seen 8 hours after cisplatin treatment in A corre-
sponds with a mitochondrial relocalization of pAKT. Purity of fractions is indicated by β-tubulin (cytoplasmic) and COX IV (mitochondrial)
markers (C).
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Here, we demonstrate that AKT activation in response to platinum
is an important mechanism underlying platinum-resistant clinical re-
lapse: the impact of AKT inhibition on both cisplatin-induced apopto-
sis and cisplatin-mediated phosphorylation of AKT are minimal in
platinum-sensitive tumor cells, whereas in resistant cells from the same
patient, S473 phosphorylation of AKT mediates platinum resistance.
Previously, constitutive activation of AKT2 has been shown to
cause cisplatin resistance in ovarian cancer models and its expression
in platinum-sensitive cells prevents cisplatin-induced down-regulation
of XIAP and represses proapoptotic BAX [2,30]. In addition, consti-
tutively active PI3K induces taxol resistance in xenograft models of
ovarian cancer; a phenotype reversed by PI3K inhibition [31]. Cis-
platin treatment of sensitive, but not resistant, cells was reported to
cause caspase-mediated cleavage and inactivation of AKT and reduced
intracellular levels of XIAP, resulting in cisplatin-induced apoptosis.
Conversely, overexpression of XIAP, a direct inhibitor of caspase 3/7,
Figure 6. DNA-PK inhibition enhances cisplatin-induced apoptosis in platinum-resistant but not platinum-sensitive cells through inhibi-
tion of AKT-S473 phosphorylation. Inhibition of DNA-PKcs phosphorylation at serine 2056 was observed from 1 to 50 μM DNA-PK in-
hibitor NU7026, consistent with DNA-PKcs autophosphorylation at this residue (A). Forty-eight hours of cisplatin treatment of
intrapatient paired platinum-sensitive (PEO1 and PEO14; 5 μM cisplatin) and -resistant (PEO4 and PEO23; 25 μM cisplatin) after serum
starvation indicates clear and significant resensitization to platinum-mediated apoptosis after 10 μM NU7026 treatment in resistant cells
(P = .0017, PEO4; P = .0004, PEO23) but no enhancement of apoptosis in sensitive cells (P = n.s.). The unmatched platinum-resistant
SKOV3 cell line behaves similarly to the other resistant lines (P= .001) (B). Western blot indicates a consistent inhibition of pAKT-S473 in
platinum- or IR-treated cells when cotreated with NU7026 for 24 hours. Conversely, AKT T308 phosphorylation is unaffected by NU7026
treatment. DNA-PK inhibition failed to prevent insulin-mediated AKT-S473 phosphorylation (C). Western blot indicates inhibition of pBAD-
S136 at 30minutes, 8 hours, and 24 hours after combined treatment with cisplatin (25 μM) and the AKT inhibitor (API-2; 10 μM) or DNA-PK
inhibitor (NU7026; 10 μM). (D) **P < .01. ***P < .001.
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promotes AKT phosphorylation and decreases cisplatin-induced apop-
tosis (reviewed in Stronach et al. [12]). Pei et al. [32] showed that
FKBP51, which promotes the dephosphorylation of AKT-S473, is asso-
ciated with sensitivity to chemotherapy, although not specifically plat-
inum agents. Platinum-treated ovarian cancer patients with complete
responses and patients with more than 6 months of progression-free
survival (platinum-sensitive) were reported to be less likely to have
PIK3CA genomic alterations at presentation than those who relapsed
within 6 months. PTEN expression has been observed to correlate with
chemosensitivity in ovarian cancer cell lines and PTEN modulation
can alter sensitivity to cisplatin (reviewed in Stronach et al. [12]). How-
ever, the studies discussed here used in vitro generated models of re-
sistance that do not arise by the same processes as the in vivo derived
lines described here [16,18], and these studies did not address the
direct link between platinum-induced DNA damage and AKT acti-
vation that suggest a nuclear AKT phosphorylation event that is dis-
tinct from the canonical activation pathway at the cell surface.
Data presented here indicate that prolonged activation of AKT in
response to cisplatin exposure is a feature acquired on the develop-
ment of clinical resistance to cisplatin within an individual patient.
Enhancement of apoptosis and accumulation of nuclear AKT are
only seen in clinically resistant cells and not in their sensitive matched
counterparts, further indicating that AKT activation prevents cisplatin-
induced apoptosis as a mechanism of clinically acquired resistance.
Numerous AKT inhibitors are currently in development with a
number in phase 1/2 trials [33,34], and so combining AKT inhibition
with conventional platinum therapy is a feasible strategy for manag-
ing clinically acquired platinum resistance. Interestingly, however, in-
hibition of AKT, or indeed IGF-1R or mTOR, has been associated
with hyperglycemia and diabetes [24,35–37]. AKT is an essential com-
ponent of the insulin signaling pathway being activated in response to
insulin stimulation through phosphorylation by PDK1/mTORC2. Ac-
tivated AKT causes translocation of GLUT4 to the plasma-membrane
facilitating glucose uptake while also inactivating GSK-3, thereby
enhancing glycogen synthesis (reviewed in Asano et al. [38]). Fur-
thermore, AKT phosphorylates and inhibits the transcription factor
FOXO1, which can suppress glucose production in the liver and kid-
ney by downregulation of phosphoenolpyruvate carboxykinase and
glucose-6-phosphatase. In addition, active AKT phosphorylates the
TSC1-TSC2 complex, leading to mTOR activation, which regulates
protein synthesis/cell growth in response to insulin (reviewed in
Avruch et al. [39]). Studies of knockout mice lacking AKT1, AKT2,
or AKT3 identified specific phenotypes relating to each isoform with
AKT2 knockout mice demonstrating insulin resistance, hyperinsu-
linemia, and glucose intolerance [25]. Our data do not support a sin-
gle AKT isoform as being responsible for the acquired resistance
to cisplatin-induced apoptosis, suggesting that implementation of
isoform-specific inhibitors may not be beneficial in this indication.
We were therefore interested in the mechanism of AKT activation
after platinum-induced DNA damage. DNA-PK is a nuclear serine/
threonine kinase composed of a 470-kDa catalytic subunit, DNA-
PKcs, and two DNA binding proteins, Ku70 and Ku80. After
DNA damage, Ku70/Ku80 detect dsDNA damage and bind DNA
double-strand breaks (DSBs) as heterodimers, subsequently attracting
the DNA-PKcs subunit and initiating nonhomologous end-joining
(NHEJ) repair. Together with ataxia-telangiectasia mutant and ataxia-
telangiectasia and Rad3 related, DNA-PK forms a critical early com-
ponent of the DNA damage response [40]. In addition to initiating
NHEJ repair, DNA-PK can activate DNA damage response signaling
cascades after activation at DSBs, for example, by regulating the p53
and AKT pathways: Feng et al. [9] demonstrated that DNA-PK had
in vitro kinase activity for S473 of AKT. Subsequently, Bozulic et al.
[8] showed that DNA-PK phosphorylates AKT on S473 in the nucleus
of HUVEC cells and is required for activation of AKT in response to
IR or doxorubicin-induced DNA damage. Our findings here indicate
that depletion of Rictor, a unique component of the known AKT-
S473 kinase mTORC2, is ineffective at preventing cisplatin-mediated
activation of AKT or in restoring platinum sensitivity to resistant cells,
indicating that cisplatin-mediated AKT activation is mTORC2 in-
dependent. In contrast, disruption of DNA-PK in our studies prevented
cisplatin-induced AKT phosphorylation at S473 and reversed the at-
tenuated apoptotic response to cisplatin in acquired platinum-resistant
cells while not interfering with insulin-mediated AKT activation. We
also showed that this reversal of cisplatin resistance was associated with
abrogation of AKT-mediated BAD phosphorylation, a phosphomodi-
fication known to inhibit the proapoptotic function of BAD [28].
Conversely, platinum-sensitive cells were not further sensitized to
platinum by these treatments, indicating an acquired mechanism spe-
cific to the platinum resistant state. In other studies, DNA-PKcs−/−
mice were used to address the physiological relevance of DNA-PK in
activation of AKT, and these showed that DNA-PKcs was required
for γIR DNA damage–induced activation but not growth factor– or
insulin-induced AKT activation and demonstrated no differences be-
tween blood glucose response between DNA-PKcs–null mice and
wild-type controls when treated with either insulin or glucose [41].
Nuclear translocation of AKT after DNA damage induced by
doxorubicin has been reported, and these studies indicated that such
DNA damage can give rise to DNA-PK–mediated phosphorylation
of AKT-S473. However, the authors argue that the phosphorylation
of T308, which they prevent by using a PI3K inhibitor, is the critical
step and that, without this, the DNA-PK–mediated S473 phosphor-
ylation will not allow sufficient AKT activity [42]. In contrast, our
findings suggest that phosphorylation of the T308 site is insufficient
to produce the AKT-mediated, platinum-resistant phenotype be-
cause our data demonstrate that loss of DNA-PK–mediated S473
phosphorylation in the presence of strong T308 phosphorylation
by targeting DNA-PK restores the apoptotic response to cisplatin
treatment in clinically resistant ovarian (and other) cancer cells.
We would further emphasize that targeting the DNA damage–specific
activator, DNA-PKcs, rather than the generic upstream activator,
PI3K, would logically produce a more phenotype-specific effect with
a mechanism that is different from the canonical PI3K/AKT pathway.
Recently, it was reported that PARP inhibition can result in phos-
phorylation of DNA-PKcs T2609 and γH2AX (S139) (known sub-
strates of DNA-PKcs) and can stimulate NHEJ in a BRCA2 mutant
background [43]. DNA-PK inhibition rescued the lethality of PARP
inhibition specifically in HR-deficient cells, suggesting that geno-
mic instability produced by NHEJ may underlie PARP inhibitor
synthetic lethality. This implies that DNA-PK inhibitors may be
better suited to HR-proficient tumors, entirely consistent with our
hypothesis of selective prosurvival activation of AKT in clinically ac-
quired platinum-resistant tumors. HR-deficient tumors tend to be
highly sensitive to cisplatin, becoming less so after selective evolution
associated with numerous molecular alterations, including reversion
of BRCA-inactivating mutations where present in the sensitive tu-
mor [18,19].
Conversely, a combinatorial selection process to identify synthetic
peptides that bind and inhibitDNA repair proteinswas recently reported
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and demonstrated that a peptide with DNA-PKcs inhibitory proper-
ties enhanced radiation-induced DSB formation and cell killing
in BRCA1- and BRCA2-deficient cells, suggesting that, in certain
circumstances, DNA-PK inhibition is compatible with a homologous
recombination–deficient background [44].
In summary, we have presented evidence that the clinically platinum-
resistant phenotype in ovarian cancer uses AKT activation by phosphor-
ylation at S473 selectively. This AKT activation in response to cisplatin
is mediated through DNA-PK using a mechanism apparently separate
from the canonical cell surface–mediated AKT activation pathway. We
therefore propose DNA-PK inhibition as a therapeutic strategy to
specifically reverse clinically acquired platinum-resistant ovarian can-
cer while avoiding the growth factor/insulin effects that may problem-
atically accompany pan-AKT inhibition.
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Table W1. Platinum Sensitivity of Ovarian Cancer Cell Lines Used.
IC50 values (μM) of cisplatin (cddp) were determined by MTT assay as described previously [1] (n = 3).
Figure W1. Densitometric analysis of Western blots was carried
out using ImageJ (http://rsbweb.nih.gov/ij/) and plotted as pAKT/
β-tubulin with data points normalized to the T 0 time point for each
cell line. Prolonged induction of AKT phosphorylation in resistant
PEO4 cells is indicated (A). Reduction of pAKT S473 using the AKT
inhibitor API-2 is shown in both the presence and absence of 25 μM
cisplatin and indicates complete lossofdetectable pAKTusing10μM
API-2 (B). Relates to Figure 1, A and B.
Figure W2. Caspase 3/7 activation assays reveal enhanced apoptotic response to a 24-hour cisplatin exposure by cotreating with the
AKT inhibitor API-2 in HCH-1 clear cell ovarian cancer cells (P = .0002; A), PANC-1 pancreatic cancer cells (P = .047; B), and PC3 pros-
tate cancer cells (P = .046) (C). Relates to Figure 1D.
Figure W3. IP of AKT in a panel of platinum-sensitive and -resistant cells indicates an interaction with DNA-PKcs by Western blot in
resistant cells, in both the presence and absence of 25 μM cisplatin (2-hour exposure), which is not seen in sensitive PEO1 and PEA1
cells, but nevertheless is detectable in sensitive PEO14 cells (A). Knockdown of DNA-PKcs in platinum-resistant PEO23 (B) and PEA2 (C)
cells increases the apoptotic induction on platinum treatment compared with control transfections. Western blots indicate knockdown
of DNA-PKcs and loss of pAKT S473. *P < .05. ***P < .001. Relates to Figure 4.
Figure W4. Immunofluorescent microscopy of platinum-sensitive (PEA1) and -resistant (PEA2) cells (A) and platinum-resistant SKOV3
cells (B) both untreated and 30 minutes after treatment with 25 μM cisplatin reveals induction and nuclear accumulation of pAKT S473 in
resistant cells only. Secondary antibody–only controls are shown (C). Counterstaining of nuclei is indicated in blue and actin (phalloidin
stain) is indicated in green in certain merged images. Relates to Figure 5.
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